Second-line chemotherapy in small cell lung cancer
- PMID: 1965533
- DOI: 10.1016/0305-7372(90)90083-r
Second-line chemotherapy in small cell lung cancer
Abstract
The literature on second-line chemotherapy in small cell lung cancer (SCLC) for the period 1979-1989 is reviewed. The reports consisted mainly of Phase II type studies and comprised a total of 987 patients with relatively few patients per study. The information was frequently incomplete with regard to duration of response on first-line chemotherapy, length of any drug-free interval and duration of response on second-line chemotherapy. The overall second-line response rate was 30%, but only 5% were complete responses (CR). The response rates obtained by the combination of cisplatinum (P) and VP-16 (E) or reinduction therapy were 45% and 64% (medians), respectively. These rates were superior to regimens consisting of supposedly non-cross-resistant agents. With P and E not given in combination, the response rates were less than 20%.
Similar articles
-
Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer -- the use of complete response rate as the primary endpoint in phase II trials.Lung Cancer. 2001 May;32(2):155-62. doi: 10.1016/s0169-5002(00)00220-8. Lung Cancer. 2001. PMID: 11325486 Review.
-
Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.J Clin Oncol. 1987 Dec;5(12):1880-9. doi: 10.1200/JCO.1987.5.12.1880. J Clin Oncol. 1987. PMID: 2824710 Clinical Trial.
-
The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer.Semin Oncol. 1986 Sep;13(3 Suppl 3):10-6. Semin Oncol. 1986. PMID: 3020692 Review.
-
A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235).Am J Clin Oncol. 2005 Feb;28(1):81-90. doi: 10.1097/01.coc.0000139940.52625.d0. Am J Clin Oncol. 2005. PMID: 15685040 Clinical Trial.
-
First-line therapy with VP-16 and cisplatin for small-cell lung cancer.Semin Oncol. 1986 Sep;13(3 Suppl 3):17-23. Semin Oncol. 1986. PMID: 3020694
Cited by
-
Chemotherapy for small cell lung cancer: a comprehensive review.Oncol Rev. 2012 Apr 2;6(1):e4. doi: 10.4081/oncol.2012.e4. eCollection 2012 Mar 5. Oncol Rev. 2012. PMID: 25992206 Free PMC article. Review.
-
Topotecan in the treatment of relapsed small cell lung cancer.Onco Targets Ther. 2008 Dec 1;1:79-86. doi: 10.2147/ott.s3689. Onco Targets Ther. 2008. PMID: 21127755 Free PMC article.
-
Treatment and outcomes for elderly patients with small cell lung cancer.Drugs Aging. 2000 Sep;17(3):229-47. doi: 10.2165/00002512-200017030-00006. Drugs Aging. 2000. PMID: 11043821 Review.
-
A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer.Br J Cancer. 1998;77(2):347-51. doi: 10.1038/bjc.1998.54. Br J Cancer. 1998. PMID: 9461009 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical